ROCKVILLE, Md., Nov. 2, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Credit Suisse 31st Annual Healthcare Conference
Date: Tuesday, November 8, 2022
Location: Terranea Resort, Rancho Palos Verdes, CA

Barclays Sixth Annual Barclays Gene Editing/Therapy Summit
Date: November 14, 2022
Panel Title: AAV Gene Therapy – Current Status and Future Direction
Panel Time: 2:50 p.m. ET


REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.


Dana Cormack
Corporate Communications 

Chris Brinzey, ICR Westwicke

(PRNewsfoto/REGENXBIO Inc.)


Cision View original content to download multimedia:


Copyright 2022 PR Newswire

Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more REGENXBIO Charts.
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more REGENXBIO Charts.